The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review


Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Fibrinolysis


Psychiatry related information on Fibrinolysis


High impact information on Fibrinolysis

  • BACKGROUND: Factor XI, a component of the intrinsic pathway of coagulation, contributes to the generation of thrombin, which is involved in both the formation of fibrin and protection against fibrinolysis [7].
  • CONCLUSIONS: Conjugated estrogen, alone or combined with progestin therapy, reduced PAI-1 levels by approximately 50 percent in postmenopausal women and was associated with enhanced systemic fibrinolysis [8].
  • These data suggest that the fundamental and possibly only essential physiological role of Plg is fibrinolysis [9].
  • We studied the role of vascular tissue plasminogen activator (t-PA), the primary mediator of fibrinolysis, in the development of this problem [10].
  • Before it was sutured, the operative field was irrigated in 19 patients with 10 ml of a 4.8 percent aqueous solution of tranexamic acid (an inhibitor of fibrinolysis) and in 20 patients with a placebo solution [11].

Chemical compound and disease context of Fibrinolysis


Biological context of Fibrinolysis


Anatomical context of Fibrinolysis


Associations of Fibrinolysis with chemical compounds


Gene context of Fibrinolysis

  • In contrast, anti-IL-6 markedly attenuated endotoxin-induced activation of coagulation, monitored with the plasma levels of the prothrombin fragment F1+2 and thrombin-antithrombin III complexes, whereas activation of fibrinolysis, determined with the plasma concentrations of plasmin-alpha 2-antiplasmin complexes, remained unaltered [30].
  • These data suggest that TM has antiinflammatory properties in addition to its role in coagulation and fibrinolysis [31].
  • These studies identify enhanced expression of PAI-1 as an important mechanism suppressing fibrinolysis under conditions of low oxygen tension, a response which may be further amplified by decreased expression of plasminogen activators [32].
  • Kininogen therefore is a critical factor required for the functioning of Hageman factor-dependent coagulation and fibrinolysis and for the activation of prekallikrein [33].
  • Tissue type plasminogen activator (tPA) is the physiological initiator of fibrinolysis, activating plasminogen via highly specific proteolysis; plasmin then degrades fibrin with relatively broad specificity [34].

Analytical, diagnostic and therapeutic context of Fibrinolysis


  1. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. Suffredini, A.F., Harpel, P.C., Parrillo, J.E. N. Engl. J. Med. (1989) [Pubmed]
  2. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators. Schömig, A., Kastrati, A., Dirschinger, J., Mehilli, J., Schricke, U., Pache, J., Martinoff, S., Neumann, F.J., Schwaiger, M. N. Engl. J. Med. (2000) [Pubmed]
  3. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. Meigs, J.B., Mittleman, M.A., Nathan, D.M., Tofler, G.H., Singer, D.E., Murphy-Sheehy, P.M., Lipinska, I., D'Agostino, R.B., Wilson, P.W. JAMA (2000) [Pubmed]
  4. Epinephrine exerts anticoagulant effects during human endotoxemia. van der Poll, T., Levi, M., Dentener, M., Jansen, P.M., Coyle, S.M., Braxton, C.C., Buurman, W.A., Hack, C.E., ten Cate, J.W., Lowry, S.F. J. Exp. Med. (1997) [Pubmed]
  5. A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis. Leebeek, F.W., Kluft, C., Knot, E.A., de Maat, M.P., Wilson, J.H. Gastroenterology (1991) [Pubmed]
  6. Erectile and endothelial dysfunction in Type II diabetes: a possible link. De Angelis, L., Marfella, M.A., Siniscalchi, M., Marino, L., Nappo, F., Giugliano, F., De Lucia, D., Giugliano, D. Diabetologia (2001) [Pubmed]
  7. High levels of coagulation factor XI as a risk factor for venous thrombosis. Meijers, J.C., Tekelenburg, W.L., Bouma, B.N., Bertina, R.M., Rosendaal, F.R. N. Engl. J. Med. (2000) [Pubmed]
  8. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. Koh, K.K., Mincemoyer, R., Bui, M.N., Csako, G., Pucino, F., Guetta, V., Waclawiw, M., Cannon, R.O. N. Engl. J. Med. (1997) [Pubmed]
  9. Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency. Bugge, T.H., Kombrinck, K.W., Flick, M.J., Daugherty, C.C., Danton, M.J., Degen, J.L. Cell (1996) [Pubmed]
  10. Vascular tissue plasminogen activator and the development of coronary artery disease in heart-transplant recipients. Labarrere, C.A., Pitts, D., Nelson, D.R., Faulk, W.P. N. Engl. J. Med. (1995) [Pubmed]
  11. Hemostatic effect of tranexamic acid mouthwash in anticoagulant-treated patients undergoing oral surgery. Sindet-Pedersen, S., Ramström, G., Bernvil, S., Blombäck, M. N. Engl. J. Med. (1989) [Pubmed]
  12. Glycoprotein inhibitors and fibrinolysis in myocardial infarction. Ring, B.L. JAMA (2000) [Pubmed]
  13. Effect of clofibrate on intravascular coagulation in hyperlipoproteinemia. Carvalho, A.C., Lees, R.S., Vaillancourt, R.A., Colman, R.W. Circulation (1977) [Pubmed]
  14. Effect of aspirin and sodium salicylate on thrombosis, fibrinolysis, prothrombin time, and platelet survival In rabbits with indwelling aortic catheters. Cattaneo, M., Chahil, A., Somers, D., Kinlough-Rathbone, R.L., Packham, M.A., Mustard, J.F. Blood (1983) [Pubmed]
  15. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1. Jänicke, F., Pache, L., Schmitt, M., Ulm, K., Thomssen, C., Prechtl, A., Graeff, H. Cancer Res. (1994) [Pubmed]
  16. Release of alpha 2-plasmin inhibitor from plasma fibrin clots by activated coagulation factor XIII. Its effect on fibrinolysis. Mimuro, J., Kimura, S., Aoki, N. J. Clin. Invest. (1986) [Pubmed]
  17. Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor. Schleef, R.R., Higgins, D.L., Pillemer, E., Levitt, L.J. J. Clin. Invest. (1989) [Pubmed]
  18. In vivo regulation of plasminogen function by plasma carboxypeptidase B. Swaisgood, C.M., Schmitt, D., Eaton, D., Plow, E.F. J. Clin. Invest. (2002) [Pubmed]
  19. Nafamostat mesilate reduces blood loss during open heart surgery. Murase, M., Usui, A., Tomita, Y., Maeda, M., Koyama, T., Abe, T. Circulation (1993) [Pubmed]
  20. Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence. Sobel, B.E., Woodcock-Mitchell, J., Schneider, D.J., Holt, R.E., Marutsuka, K., Gold, H. Circulation (1998) [Pubmed]
  21. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Hajjar, K.A., Gavish, D., Breslow, J.L., Nachman, R.L. Nature (1989) [Pubmed]
  22. Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes. Murciano, J.C., Medinilla, S., Eslin, D., Atochina, E., Cines, D.B., Muzykantov, V.R. Nat. Biotechnol. (2003) [Pubmed]
  23. Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: a mechanism for arterial thrombosis and myocardial infarction. Newby, D.E., Wright, R.A., Labinjoh, C., Ludlam, C.A., Fox, K.A., Boon, N.A., Webb, D.J. Circulation (1999) [Pubmed]
  24. Induction of expression of monocyte interleukin 1 by Hageman factor (factor XII). Toossi, Z., Sedor, J.R., Mettler, M.A., Everson, B., Young, T., Ratnoff, O.D. Proc. Natl. Acad. Sci. U.S.A. (1992) [Pubmed]
  25. The cleavage and inactivation of plasminogen activator inhibitor type 1 by neutrophil elastase: the evaluation of its physiologic relevance in fibrinolysis. Wu, K., Urano, T., Ihara, H., Takada, Y., Fujie, M., Shikimori, M., Hashimoto, K., Takada, A. Blood (1995) [Pubmed]
  26. Increased blood fibrinolytic activity after aspirin ingestion. Moroz, L.A. N. Engl. J. Med. (1977) [Pubmed]
  27. Paradoxical rescue from ischemic lung injury by inhaled carbon monoxide driven by derepression of fibrinolysis. Fujita, T., Toda, K., Karimova, A., Yan, S.F., Naka, Y., Yet, S.F., Pinsky, D.J. Nat. Med. (2001) [Pubmed]
  28. Inhibition of plasmin-mediated fibrinolysis by vitamin E. Moroz, L.A., Gilmore, N.J. Nature (1976) [Pubmed]
  29. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. Levi, M., ten Cate, H., Bauer, K.A., van der Poll, T., Edgington, T.S., Büller, H.R., van Deventer, S.J., Hack, C.E., ten Cate, J.W., Rosenberg, R.D. J. Clin. Invest. (1994) [Pubmed]
  30. Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. van der Poll, T., Levi, M., Hack, C.E., ten Cate, H., van Deventer, S.J., Eerenberg, A.J., de Groot, E.R., Jansen, J., Gallati, H., Büller, H.R. J. Exp. Med. (1994) [Pubmed]
  31. The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways. Conway, E.M., Van de Wouwer, M., Pollefeyt, S., Jurk, K., Van Aken, H., De Vriese, A., Weitz, J.I., Weiler, H., Hellings, P.W., Schaeffer, P., Herbert, J.M., Collen, D., Theilmeier, G. J. Exp. Med. (2002) [Pubmed]
  32. Coordinated induction of plasminogen activator inhibitor-1 (PAI-1) and inhibition of plasminogen activator gene expression by hypoxia promotes pulmonary vascular fibrin deposition. Pinsky, D.J., Liao, H., Lawson, C.A., Yan, S.F., Chen, J., Carmeliet, P., Loskutoff, D.J., Stern, D.M. J. Clin. Invest. (1998) [Pubmed]
  33. Williams trait. Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways. Colman, R.W., Bagdasarian, A., Talamo, R.C., Scott, C.F., Seavey, M., Guimaraes, J.A., Pierce, J.V., Kaplan, A.P. J. Clin. Invest. (1975) [Pubmed]
  34. Lysine 156 promotes the anomalous proenzyme activity of tPA: X-ray crystal structure of single-chain human tPA. Renatus, M., Engh, R.A., Stubbs, M.T., Huber, R., Fischer, S., Kohnert, U., Bode, W. EMBO J. (1997) [Pubmed]
  35. Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Avvisati, G., ten Cate, J.W., Büller, H.R., Mandelli, F. Lancet (1989) [Pubmed]
  36. Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction. Collen, D., Bounameaux, H., De Cock, F., Lijnen, H.R., Verstraete, M. Circulation (1986) [Pubmed]
  37. A monoclonal antibody preventing binding of tissue-type plasminogen activator to fibrin: useful to monitor fibrinogen breakdown during t-PA infusion. Holvoet, P., Lijnen, H.R., Collen, D. Blood (1986) [Pubmed]
  38. Effects of hyperthermic isolated limb perfusion with recombinant tumor necrosis factor alpha and melphalan on the human fibrinolytic system. Zwaveling, J.H., Maring, J.K., Mulder, A.B., Bom, V.J., van Ginkel, R.J., Schraffordt Koops, H., Girbes, A.R., Hoekstra, H.J., van der Meer, J. Cancer Res. (1996) [Pubmed]
  39. tPA receptors and the fibrinolytic response in multiple sclerosis lesions. Gveric, D., Herrera, B.M., Cuzner, M.L. Am. J. Pathol. (2005) [Pubmed]
WikiGenes - Universities